Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ARTVBullishIndustry Newsnews

High materiality7/10

Artiva reports six-month Sjögren data; Phase 3 RA catalyst expected

Oct 1, 2026, 7:56 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive interim efficacy signals and durable safety with outpatient use reduce risk and improve the near-term value proposition; Phase 3 RA readout timing could uplift valuation if data durability is confirmed.

AI summary

What happened, with direct paths to the underlying reporting

Artiva presented six-month data for AlloNK in Sjögren's disease showing meaningful improvements in systemic activity and symptoms, with salivary function rising to normal levels in a subset. Across 73 patients in the Phase 2a basket, safety signals were favorable, with no CRS or ICANS and outpatient administration feasible. The company plans a Phase 3 RA trial in H2 2026, signaling a near-term clinical and valuation catalyst if durability remains evident.

Six-month Sjögren's data from 11 patients show meaningful improvements.
ClinESSDAI down 6.9 pts; ESSPRI down 3.5, both above MCII.
Salivary flow rose 0.4 to 1.1 mL/min in 8 patients.
No CRS or ICANS; safety supports outpatient AlloNK administration.
Phase 3 RA trial planned for H2 2026; broader autoimmune program progress.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.